AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31077579 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA (general)
Number of subjects: 14
Study 31077699 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) for pEGC
Number of subjects: 121
Study 31077699 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD) for pEGC outside criteria
Number of subjects: 121
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: HLE present at day 0
Number of subjects: 78
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII activity >160%
Number of subjects: 78
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of protein C <34%
Number of subjects: 78
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin activity <28%
Number of subjects: 78
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: International normalized ratio >2.6
Number of subjects: 78
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII activity
Number of subjects: 78
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: International normalized ratio
Number of subjects: 78
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of protein C
Number of subjects: 78
Study 31077821 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for end-stage liver disease score
Number of subjects: 78
Study 31077981 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-life depression (LLD)
Number of subjects: 44
Study 31078447 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based prototype of a discharge report for the community pharmacist
Number of subjects: 19
Study 31078468 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of acute lymphoblastic leukaemia
Number of subjects: 980
Study 31078468 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 980
Study 31078468 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors treated on protocols between 1962-91
Number of subjects: 980
Study 31078468 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors treated on protocols between 1991-2007
Number of subjects: 980
Study 31078541 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Neovascularization of the Disc (NVD)
Number of subjects: 38
Study 31078541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Index (ISI)
Number of subjects: 38
Study 31078541 — intervention group
Group type: EXPERIMENTAL
Intervention: Neovascularization Elsewhere (NVE)
Number of subjects: 38
Study 31078541 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of NVE in the posterior polar retina
Number of subjects: 38
Study 31078541 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall global ischemia
Number of subjects: 38
Study 31079357 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg qd for 12 weeks
Number of subjects: 0
Study 31080027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 2492
Study 31080027 — intervention group
Group type: COMPARATOR
Intervention: Outpatient management (discharged patients)
Number of subjects: 2492
Study 31080027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization (after propensity score matching)
Number of subjects: 2492
Study 31080027 — intervention group
Group type: COMPARATOR
Intervention: Outpatient management (discharged patients after propensity score matching)
Number of subjects: 2492
Study 31080494 — intervention group
Group type: EXPERIMENTAL
Intervention: INET (intra-neuroendoscopic technique)
Number of subjects: 98
Study 31080494 — intervention group
Group type: COMPARATOR
Intervention: CPDO (cranial puncture and drainage operation)
Number of subjects: 98
Study 31080494 — intervention group
Group type: EXPERIMENTAL
Intervention: INET
Number of subjects: 98
Study 31080608 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange
Number of subjects: 299
Study 31080608 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 299
Study 31080731 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise (MCE) plus Patient Education (PE)
Number of subjects: 120
Study 31080731 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise (MCE)
Number of subjects: 120
Study 31080731 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Education (PE)
Number of subjects: 120
Study 31080813 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 40
Study 31081020 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hourly lopinavir/ritonavir dosing strategy
Number of subjects: 11
Study 31081589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium glucose cotransporter type 2 inhibitors (SGLT-2i)
Number of subjects: 0
Study 31082360 — intervention group
Group type: EXPERIMENTAL
Intervention: FET procedure with debranch-first technique
Number of subjects: 34
Study 31082392 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically assisted capsule endoscopy (MACE)
Number of subjects: 33
Study 31082392 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 33
Study 31082539 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 1116
Study 31082665 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 179
Study 31082665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 31082688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) with or without chemotherapy
Number of subjects: 36
Study 31083725 — intervention group
Group type: COMPARATOR
Intervention: Updated Diamond-Forrester (UDF) model
Number of subjects: 1675
Study 31083725 — intervention group
Group type: COMPARATOR
Intervention: CAD Consortium Basic model
Number of subjects: 1675
Study 31083725 — intervention group
Group type: COMPARATOR
Intervention: CAD Consortium Clinical model
Number of subjects: 1675
Study 31083725 — intervention group
Group type: COMPARATOR
Intervention: CAD Consortium Clinical + CACS model
Number of subjects: 1675
Study 31083725 — intervention group
Group type: COMPARATOR
Intervention: UDF model
Number of subjects: 1675
Study 31084325 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 24040
Study 31084325 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 24040
Study 31084325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 24040
Study 31084325 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, Warfarin, DOAC
Number of subjects: 24040
Study 31084335 — intervention group
Group type: EXPERIMENTAL
Intervention: Surpass Flow Diverter
Number of subjects: 180
Study 31084544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
Number of subjects: 277
Study 31084544 — intervention group
Group type: COMPARATOR
Intervention: Cytoreductive surgery alone (CRSa)
Number of subjects: 277
Study 31084924 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured GFR using iohexol clearance
Number of subjects: 20
Study 31084924 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated GFR using creatinine and cystatin C in MDRD or CKD-EPI equations
Number of subjects: 20
Study 31084936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic laminate veneers with immediate dentin sealing (IDS)
Number of subjects: 104
Study 31084936 — intervention group
Group type: COMPARATOR
Intervention: Ceramic laminate veneers without immediate dentin sealing (IDS)
Number of subjects: 104
Study 31084936 — intervention group
Group type: COMPARATOR
Intervention: Ceramic laminate veneers on teeth with pre-existing resin composite restorations
Number of subjects: 104
Study 31084936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic laminate veneers on teeth without pre-existing resin composite restorations
Number of subjects: 104
Study 31084936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic laminate veneers on vital teeth
Number of subjects: 104
Study 31084936 — intervention group
Group type: COMPARATOR
Intervention: Ceramic laminate veneers on non-vital teeth
Number of subjects: 104
Study 31084936 — intervention group
Group type: COMPARATOR
Intervention: Ceramic laminate veneers on endodontically-treated teeth
Number of subjects: 104
Study 31084936 — intervention group
Group type: COMPARATOR
Intervention: Patients who smoked
Number of subjects: 104
Study 31084936 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 104
Study 31085321 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic PFA
Number of subjects: 81
Study 31085321 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic PFA
Number of subjects: 81
Study 31085321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both monophasic and biphasic PFA
Number of subjects: 81
Study 31085605 — intervention group
Group type: EXPERIMENTAL
Intervention: iReadMore therapy (a therapy app for reading training)
Number of subjects: 0
Study 31085677 — intervention group
Group type: EXPERIMENTAL
Intervention: BabyLux device
Number of subjects: 30
Study 31085677 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximeter
Number of subjects: 30
Study 31085763 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination BRAF and MEK inhibition
Number of subjects: 1
Study 31085763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib therapy
Number of subjects: 1
Study 31085763 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of KRAS G12V mutation
Number of subjects: 1
Study 31085763 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Number of subjects: 1
Study 31085817 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath VOC MAGIIC biomarker
Number of subjects: 301
Study 31085945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) flow cytometry analysis in patients with postoperative cognitive dysfunction.
Number of subjects: 10
Study 31085945 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) flow cytometry analysis in matched controls without postoperative cognitive dysfunction.
Number of subjects: 10
Study 31086307 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 L alglucosidase alfa
Number of subjects: 113
Study 31087226 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 1292
Study 31087226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study 31087382 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg vaccine (Engerix-B) as challenge dose
Number of subjects: 0
Study 31087388 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 (n = 28 [14.7%])
Number of subjects: 221
Study 31087388 — intervention group
Group type: COMPARATOR
Intervention: Class 2 (n = 162 [85.3%])
Number of subjects: 221
Study 31087457 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I defect (infraosseous)
Number of subjects: 47
Study 31087457 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II defect (horizontal)
Number of subjects: 47
Study 31087457 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III defect (combined)
Number of subjects: 47
Study 31087457 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity M (moderate)
Number of subjects: 47
Study 31087457 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity S (slight)
Number of subjects: 47
Study 31087457 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal bone loss
Number of subjects: 47
Study 31087457 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 47
Study 31087457 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking habit
Number of subjects: 47
Study 31087772 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapies (LRT)
Number of subjects: 2019
Study 31087772 — intervention group
Group type: EXPERIMENTAL
Intervention: One single LRT
Number of subjects: 2019
Study 31087772 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-3 LRTs
Number of subjects: 2019
Study 31087772 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥4 LRTs
Number of subjects: 2019
Study 31087772 — intervention group
Group type: COMPARATOR
Intervention: LRTs (up to 3)
Number of subjects: 2019
Study 31088152 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH-C
Number of subjects: 80
Study 31088152 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH-D
Number of subjects: 80
Study 31088152 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 80
Study 31088520 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatically activated network of trained volunteers via smartwatch and smartphone applications (Intervention Group)
Number of subjects: 134
Study 31088520 — intervention group
Group type: COMPARATOR
Intervention: Emergency health services only (Control Group)
Number of subjects: 134
Study 31088560 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity level (PAL)
Number of subjects: 2190
Study 31088560 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity measured by YPAS
Number of subjects: 2190
Study 31088560 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory symptoms assessment
Number of subjects: 2190
Study 31088809 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily or 200 mg once daily
Number of subjects: 33
Study 31088809 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 33
Study 31088831 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib (oral pan-FGFR inhibitor)
Number of subjects: 187
Study 31089278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bu-Oral (oral busulfan)
Number of subjects: 40
Study 31089278 — intervention group
Group type: COMPARATOR
Intervention: Bu-IV (intravenous busulfan)
Number of subjects: 40
Study 31089682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4033
Study 31089682 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4033
Study 31089682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (quartile of largest weight loss after 1 year)
Number of subjects: 4033
Study 31089682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (after adjustment for confounders)
Number of subjects: 4033
Study 31089689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplement (1.0 μmol [14,15]-13C2-retinyl acetate)
Number of subjects: 94
Study 31089689 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine 200,000 IU vitamin A capsule administered after RID test
Number of subjects: 94
Study 31089689 — intervention group
Group type: COMPARATOR
Intervention: Consumption of liver ≥1/month
Number of subjects: 94
Study 31089689 — intervention group
Group type: COMPARATOR
Intervention: Receiving 2 or 3 vitamin A supplements in the past 12 months
Number of subjects: 94
Study 31089689 — intervention group
Group type: COMPARATOR
Intervention: High baseline total body stores of vitamin A
Number of subjects: 94
Study 31089967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 16
Study 31089967 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy lean volunteers)
Number of subjects: 16
Study 31090044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg subcutaneously every 2 weeks for 24 weeks
Number of subjects: 132
Study 31090044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg subcutaneously every 2 weeks for 24 weeks
Number of subjects: 132
Study 31092022 — intervention group
Group type: EXPERIMENTAL
Intervention: AFEQT questionnaire assessment at baseline and 1 year
Number of subjects: 1347
Study 31092022 — intervention group
Group type: EXPERIMENTAL
Intervention: AFEQT subscale Activities of Daily Living
Number of subjects: 1347
Study 31092022 — intervention group
Group type: EXPERIMENTAL
Intervention: AFEQT subscale Symptoms
Number of subjects: 1347
Study 31092023 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization during index hospitalization (70.2% of the cohort)
Number of subjects: 3387
Study 31092023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Global Registry of Acute Coronary Events scores at admission
Number of subjects: 3387
Study 31092023 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer length of stay
Number of subjects: 3387
Study 31092023 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital recurrent angina
Number of subjects: 3387
Study 31092023 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction <0.4
Number of subjects: 3387
Study 31092023 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital complication
Number of subjects: 3387
Study 31092023 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment-elevation myocardial infarction
Number of subjects: 3387
Study 31092170 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC
Number of subjects: 1328
Study 31092170 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC with clinically relevant anticoagulatory effect
Number of subjects: 1328
Study 31092203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 276
Study 31092478 — intervention group
Group type: EXPERIMENTAL
Intervention: Iatrogenic hyperinsulinemia
Number of subjects: 3
Study 31092478 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia
Number of subjects: 3
Study 31092592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC)
Number of subjects: 133
Study 31092592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (ETOH)
Number of subjects: 133
Study 31092592 — intervention group
Group type: EXPERIMENTAL
Intervention: OMNIgene.SPUTUM (OMNI)
Number of subjects: 133
Study 31092709 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi consensus process with 50 patients and 116 health professionals
Number of subjects: 166
Study 31092713 — intervention group
Group type: EXPERIMENTAL
Intervention: iSLE/iLN
Number of subjects: 216
Study 31092713 — intervention group
Group type: EXPERIMENTAL
Intervention: iLN
Number of subjects: 216
Study 31092713 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 216
Study 31092713 — intervention group
Group type: COMPARATOR
Intervention: SLE
Number of subjects: 216
Study 31092732 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified fresh Tregs (91%-96% purity)
Number of subjects: 12
Study 31092732 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved Tregs
Number of subjects: 12
Study 31092732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Tregs
Number of subjects: 12
Study 31093270 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS on the contralesional M1 and anodal tDCS on the ipsilesional M1
Number of subjects: 21
Study 31093541 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days clarithromycin
Number of subjects: 4372
Study 31093541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372
Study 31093566 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP40 wearable monitoring device
Number of subjects: 250
Study 31093566 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring devices
Number of subjects: 250
Study 31093598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 120
Study 31093864 — intervention group
Group type: EXPERIMENTAL
Intervention: Liaoning score (non-invasive prediction score for esophageal varices)
Number of subjects: 363
Study 31093864 — intervention group
Group type: EXPERIMENTAL
Intervention: Liaoning score (non-invasive prediction score for esophageal varices) in patients with AUGIB
Number of subjects: 363
Study 31093864 — intervention group
Group type: EXPERIMENTAL
Intervention: Liaoning score (non-invasive prediction score for esophageal varices) in patients without AUGIB
Number of subjects: 363
Study 31094335 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching the VIA/VILI procedure on a digital screen (IG)
Number of subjects: 118
Study 31094335 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) without watching the procedure
Number of subjects: 118
Study 31094345 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile and Web-based complementary and integrative health (CIH) programs
Number of subjects: 456
Study 31094345 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 456
Study 31094744 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline to increase mean arterial pressure to 85-90 mm Hg
Number of subjects: 40
Study 31094744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention for mean arterial pressure)
Number of subjects: 40
Study 31094777 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative residual neuromuscular blockade
Number of subjects: 2233
Study 31094790 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) examination
Number of subjects: 95
Study 31094790 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin level
Number of subjects: 95
Study 31094790 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP level
Number of subjects: 95
Study 31094790 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS abnormalities
Number of subjects: 95
Study 31094795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial Baxter Retching Faces (BARF) scale
Number of subjects: 192
Study 31095282 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest egg intake quartile
Number of subjects: 1950
Study 31095282 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest cholesterol intake quartile
Number of subjects: 1950
Study 31095300 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model of personalized postprandial glycemic response to foods trained on Israeli cohort meals
Number of subjects: 327
Study 31095300 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model of personalized postprandial glycemic response to foods trained on meals from both cohorts
Number of subjects: 327
Study 31095300 — intervention group
Group type: COMPARATOR
Intervention: Predictive model considering carbohydrate content
Number of subjects: 327
Study 31095300 — intervention group
Group type: COMPARATOR
Intervention: Predictive model considering calorie content
Number of subjects: 327
Study 31095417 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity modification and load management intervention
Number of subjects: 151